Short-term (2 weeks) administration of the TLR4 agonist, LPS, induced NF-κB activation, increased IL-6 concentration (in plasma and right atrium), and increased vulnerability to AF in a canine model of systemic inflammation. Here, IL6 is linked to atrial fibrillation.